Index. Note: Page numbers of article titles are in boldface type.
|
|
- Baldwin Garry Sherman
- 5 years ago
- Views:
Transcription
1 Heart Failure Clin 2 (2006) Index Note: Page numbers of article titles are in boldface type. A ACE inhibitors, in diabetic hypertension, Adipokines, cardiovascular events related to, 6 Advanced glycosylation end products, as cause of diabetic cardiomyopathy, 73 glucose toxicity and, 63 Albuminuria, and cardiovascular risk, antihypertensive agents and, blood pressure goals in, 57 Amylinomimetics, glucose control and, 66 Angiotensin II, adverse cardiovascular effects of, 81, 82 Angiotensin receptor blockers, as shield against consequences of insulin resistance, in chronic heart failure, 83 in clinical practice, 86 in diabetic hypertension, 31 mechanisms of action of, 81 rationale and indications for, in heart failure, Antidiabetic therapy, and lipids, Antihypertensive agents, and albuminuria, Atorvastatin, Atrial fibrillation, obesity as risk factor for, 5 B Beta blockade, in diabetic heart failure, experience with, in heart failure clinical trials, safety of, Beta blockers, benefits of, in diabetic patients, 90 cardiovascular benefits of, in diabetic patients, 90 cardiovascular effects of, effect in diabetic and nondiabetic heart failure, 92 in diabetic hypertension, metabolic effects of, noncardiovascular concerns in, in diabetic patients, 90 Beta-blocking medications, as standard therapy for heart failure, 18 Biguanides, glucose control and, 67 Blood pressure, goals for, in albuminuria, 57 Bucindolol, in heart failure, 92 C C-reactive protein, coronary artery disease and, 5, 6 Calcium channel blockers, in diabetic hypertension, 32 Candesartan, CHARM trials of, in heart failure, 84, 85 Cardiometabolic syndrome, hypertension in, Cardiomyopathy, and diabetes, association of, 72 diabetic. See Diabetic cardiomyopathy. lipid, of insulin resistance, Cardiovascular disease, and diabetic hypertension, 26 and insulin resistance, mechanics linking, 4 7 diabetes and, 45 in type 2 diabetes, 25 mortality in, and kidney disease progression, macroalbuminuria level and, Cardiovascular endpoints, lipids, diabetes mellitus and, 48 Cardiovascular risk, albuminuria and, Carvedilol, in heart failure, 92, 93 CHARM-Added trial, 85 CHARM-Alternative trial, 85 CHARM-Preserved trial, /06/$ see front matter D 2006 Elsevier Inc. All rights reserved. doi: /s (06) heartfailure.theclinics.com
2 102 INDEX CHARM trials, of candesartan, in heart failure, 84, 85 Clonidine, in diabetic hypertension, 32 Congestive heart failure, after myocardial infarction, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in, and diabetes, 72 angiotensin-converting enzyme inhibitors in, and angiotensin receptor blockers in, compared, angiotensin receptor blockers in, in angiotensinconverting enzyme inhibitor intolerance, 85 chronic, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in, metabolic syndrome as cause of, 1 Copper metabolism, diabetic cardiomyopathy and, 74 Coronary artery disease, C-reactive protein and, 5, 6 D Diabetes mellitus, altered triglyceride metabolism in, 39 and cardiomyopathy, association of, 72 and cardiovascular disease, 45 congestive heart failure and, 72 heart failure and, 41 heart failure as risk factor for, 72 hospitalization in heart failure in, 71 hypertension in, and weight loss in, body composition and fat distribution in, 29 cardiovascular disease in, 26 inflammation and oxidative stress in, 29 management of, nonpharmacologic treatment of, pathophysiology of, pharmacotherapy in, renin-angiotensin-aldosterone system activation in, 28 sodium and volume retention in, stroke in, 26 sympathetic nervous system activity and, 28 incidence of, 25 insulin resistance and, 89 lipid-lowering therapy in, effectiveness of, 42 lipids, and cardiovascular endpoints, 48 niacin in, clinical trial data on, type 2, 1 cardiovascular disease in, 25 fixed-dose combinations in, incidence of heart failure in, 41, 42 treatment of, 65 Diabetic cardiomyopathy, autonomic dysfunction in, causes of, advanced glycosylation end products as, 73 metabolic defects as, diagnosis of, epidemiology of, microvascular disease and, 74 prevalence of, 72 risk factors for, 75 role of lipotoxicity in, 74 screening for, 76 sympathetic and renin-angiotensin activation in, 75 treatment of, Diabetic dyslipidemia, 5 and cardiac dysfunction, low-density and high-density lipoprotein changes in, 39 management of, clinical trials on, pathophysiology of, treatment considerations in, treatment goals in, 46 Diabetic heart failure, and nondiabetic heart failure, effect of beta blockers in, 92 beta blockade in, experience with, in heart failure clinical trials, safety of, Diabetic nephropathy, in hypertension, 26 Diabetic patients, in heart failure trials, meta-analyses of, Diet, in diabetic hypertension, 30 Dyslipidemia, in diabetes. See Diabetic dyslipidemia. E ELITE trials, in congestive heart failure, 84 End-stage renal disease, 53 Exercise, in diabetic hypertension, 30 F Fat distribution, Fatty acids, free, lipotoxicity and, 62 Fenofibrate, 44 Fetal gene program, in diabetic cardiomyopathy, 74 Fibrinolysis, impaired, in metabolic syndrome, 7
3 INDEX 103 Framingham Heart Study, diabetic cardiomyopathy and, 71 Free fatty acids, lipotoxicity and, 62 G Glucose toxicity, advanced glycation end points and, 63 cellular responses to, balancing of, oxidative stress and, à-glucosidase inhibitors, glucose control and, 67 Glycosylation end products, advanced, as cause of diabetic cardiomyopathy, 73 glucose toxicity and, 63 H Heart, diabetic, activation of sympathetic nervous system in, 17 diabetic dyslipidemia and, effect of hyperglycemia and its therapies on, Heart disease, ischemic, hyperinsulinemia as risk factor for, 3 lipotoxic, Heart failure, as risk factor for diabetes, 72 beta-blocking medications as standard therapy for, 18 chronic, angiotensin receptor blockers in, 83 compensated, thiazolidinediones in, 18 congestive. See Congestive heart failure. diabetes and, 41, 42 diabetic. See Diabetic heart failure. hospitalization in, in diabetes, 71 inflammation, and insulin resistance, 17 metabolic syndrome and, 1 11 rationale and indications for angiotensin receptor bloockers in, Heart failure trials, diabetic subjects in, meta-analyses of, Hydralazine, in diabetic hypertension, 32 Hyperglycemia, and insulin resistance, 4 effect of, and effect of therapies on heart, Hyperinsulinemia, as risk factor for ischemic heart disease, 3 Hyperlipidemia, and diabetes, 5 Hypertension, and insulin resistance, 4, 27 diabetic, body composition and fat distribution in, 29 cardiovascular disease and, 26 inflammation and oxidative stress in, 29 management of, nonpharmacologic treatment of, pharmacotherapy in, renin-angiotensin-aldosterone system activation in, 28 sodium and volume retention in, 28 stroke in, 26 sympathetic nervous system activity and, 28 weight loss in, diabetic nephropathy in, 26 in cardiometabolic syndrome, pathophysiology of, in patient with diabetes mellitus, vascular/endothelial dysfunction in, I Incretin mimetics, insulin secretion and, 66 Inflammation, cardiovascular events related to, 5 7 insulin resistance, and heart failure, 17 lipotoxicity and, Insulin resistance, and cardiovascular disease, mechanics linking, 4 7 cardiomyopathy of, and response to treatment, 14 energy metabolism of, epidemiologic and clinical evidence of, pathophysiologic links in, consequences of, angiotensin receptor blockers as shield against, diabetes and, 89 diastolic dysfunction as manifestation of, 17 energy deficit, and uncoupling proteins, energy metabolism, and heart failure, 16 hypertension and, 4, 27 inflammation, and heart failure, 17 measurement of, 3 moderate hyperglycemia and, 4 obesity and, 4 5 thiazolidinediones in, 7 8 treatment of, therapy targets in, Insulin resistance syndrome. See also Metabolic syndrome. K Kidney disease, chronic, 53 epidemiology of, 53 progression of, macroalbuminuria, and cardiovascular mortality, 54 56
4 104 INDEX L Lipid cardiomyopathy, Lipid-lowering agents, 43 Lipid-lowering therapy, in diabetes, effectiveness of, 42 Lipids, antidiabetic therapy and, cardiovascular endpoints, diabetes mellitus and, 48 Lipoapoptosis, 38 Lipoproteins, changes in, in diabetic dyslipidemia, 39 Lipotoxic heart disease, Lipotoxicity, cellular responses to, balancing of, free fatty acids and, 62 inflammation and, role in diabetic cardiomyopathy, 74 N Nebivolol, in heart failure, Nephropathy, diabetic, in hypertension, 26 Neuropathy, cardiovascular autonomic, Niacin, in diabetes, clinical trial data on, O Obesity, and insulin resistance, 4 5 as risk factor for atrial fibrillation, 5 cardiac failure in, 5 OPTIMAAL trial, post-myocardial infarction, 84 Oxidative stress, cellular responses to, balancing of, glucose toxicity and, M Macroalbuminuria, blood pressure and, 56 kidney disease progression, and cardiovascular mortality, outcome trials and, Metabolic defects, as cause of diabetic cardiomyopathy, 73 Metabolic syndrome, as cause of congestive heart failure, 1 criteria for diagnosis of, 2, 38 definition of, 1 heart failure and, 1 11 impact of treatments on, 7 8 incidence of, 1 prevalence and antecedents of, 1 risk for congestive heart failure, 7 8 Metaprolol, in heart failure, 92 Metformin, in diabetic cardiomyopathy, Microalbuminuria, as cardiovascular marker, blood pressure and, 56 cardiovascular events related to, 7 evaluation and work-up of, 56, 57 Microvascular disease, diabetic cardiomyopathy and, 74 Muraglitazar, in diabetic cardiomyopathy, 77 Myocardial infarction, congestive heart failure after, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in, P Pramlintide, glucose control and, 66 Protein, C-reactive, coronary artery disease and, 5, 6 Proteinuria, blood pressure and, 56 kidney disease progression, and cardiovascular mortality, outcome trials and, R Renin-angiotensin-aldosterone system, activation of, S Secretogogues, to increase insulin secretion, Sodium retention, in diabetic hypertension, 28 Stroke, and diabetic hypertension, 26 Sympathetic nervous system, activation of, and diabetic heart, 17 activity of, in diabetic hypertension, 28 T Thiazide diuretics, in diabetic hypertension, 32 Thiazolidinediones, glucose control and, in compensated heart failure, 18
5 INDEX 105 in diabetic cardiomyopathy, in insulin resistance, 7 8 Triglycerides, accumulation in heart, altered metabolism of, in diabetes mellitus, 39 VALIANT trial, post-myocardial infarction, 84 Vascular/endothelial dysfunction, in hypertension, V Val-HeFT trial, 85 W Weight loss, in hypertension and diabetes, 29 30
Metabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationCondition/Procedure Measure Compliance Criteria Reference Attribution Method
Premium Specialty: Cardiology Credentialed Specialties include: Cardiac Diagnostic, Cardiology, Cardiovascular Disease, Clinical Cardiac Electrophysiology, and Interventional Cardiology This document is
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationSince the initial description of angiotensin II mediated
CLINICAL CARDIOLOGY: PHYSICIAN UPDATE Manipulation of the Renin-Angiotensin System Michael M. Givertz, MD Since the initial description of angiotensin II mediated hypertension 40 years ago, basic and clinical
More informationABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour
ABCD and Renal Association Clinical Guidelines for Diabetic Nephropathy-CKD. Management of Dyslipidaemia and Hypertension in Adults Dr Peter Winocour Dr Indranil Dasgupta Rationale No national practical
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A ACCORD (Action to Control Cardiovascular Disease and Diabestes), blood pressure goal, 74 ACEIs (Angiotensin-converting enzyme inhibitors),
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationCardiac Pathophysiology
Cardiac Pathophysiology Evaluation Components Medical history Physical examination Routine laboratory tests Optional tests Medical History Duration and classification of hypertension. Patient history of
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationSubject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119
Acarbose, diabetes prevention trials 32, 33, 40 42 Accelerator hypothesis accelerators beta cell autoimmunity 140, 141, 147, 150, 151 insulin resistance 140, 142 144, 150 obesity 145 148 diabetes risk
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationHypertension Management Focus on new RAAS blocker. Disclosure
Hypertension Management Focus on new RAAS blocker Rameshkumar Raman M.D Endocrine Associates of The Quad Cities Disclosure Speaker bureau Abbott, Eli Lilly, Novo Nordisk, Novartis, Takeda, Merck, Solvay
More informationComplications of Diabetes mellitus. Dr Bill Young 16 March 2015
Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationDiabetes and Kidney Disease. Kris Bentley Renal Nurse practitioner 2018
Diabetes and Kidney Disease Kris Bentley Renal Nurse practitioner 2018 Aims Develop an understanding of Chronic Kidney Disease Understand how diabetes impacts on your kidneys Be able to recognise the risk
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationDRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)
DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS) Beta-blockers have been widely used in the management of angina, certain tachyarrhythmias and heart failure, as well as in hypertension. Examples
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationWomen s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women
Women s Heart Health: Holistic Approaches Throughout the Lifetime - Key Differences in Heart Failure in Women C. Noel Bairey Merz MD Medical Director and Barbra Streisand Women s Heart Center Preventive
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationDysglycaemia and Hypertension. Dr E M Manuthu Physician Kitale
Dysglycaemia and Hypertension Dr E M Manuthu Physician Kitale None Disclosures DM is MI equivalent MR FIT Objective was to assess predictors of CVD mortality among men with and without diabetes and
More informationChapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure
Chapter 10 Congestive Heart Failure Learning Objectives Explain concept of polypharmacy in treatment of congestive heart failure Explain function of diuretics Learning Objectives Discuss drugs used for
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationCKD Satellite Symposium
CKD Satellite Symposium Recommended Therapy by Heart Failure Stage AHA/ACC Task Force on Practice Guideline 2001 Natural History of Heart Failure Patients surviving % Mechanism of death Sudden death 40%
More informationHypertension and obesity. Dr Wilson Sugut Moi teaching and referral hospital
Hypertension and obesity Dr Wilson Sugut Moi teaching and referral hospital No conflict of interests to declare Obesity Definition: excessive weight that may impair health BMI Categories Underweight BMI
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationAsthma J45.20 Mild, uncomplicated J45.21 Mild, with (acute) exacerbation J45.22 Mild, with status asthmaticus
A Fib & Flutter I48.0 Paroxysmal atrial fibrillation I48.1 Persistent atrial fibrillation I48.2 Chronic atrial fibrillation I48.3 Typical atrial flutter Asthma J45.20 Mild, uncomplicated J45.21 Mild, with
More informationProf. Andrzej Wiecek Department of Nephrology, Endocrinology and Metabolic Diseases Medical University of Silesia Katowice, Poland.
What could be the role of renal denervation in chronic kidney disease? Andrzej Wiecek, Katowice, Poland Chairs: Peter J. Blankestijn, Utrecht, The Netherlands Jonathan Moss, Glasgow, UK Prof. Andrzej Wiecek
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationPrevention of Cardiovascular Events in Hypertension and CAD & Management of Hypertension in HF of Ischemic origin
"Insight Heart" is also available at www.squarepharma.com.bd Vol: 911 No: 4; 4; 2012 2015 Prevention of Cardiovascular Events in Hypertension and CAD Drug-eluting & Management of Hypertension in HF of
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationManagement of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE
Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationClinical Approach to Achieving Treatment Targets: Case Vignette Discussion
Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion Om P. Ganda, MD; Kirit Tolia, MD, FACE Postcardiac Follow-up in a 66-Year-Old Man Slide 1. Dr. Ganda: Now we will present a case
More informationManagement of Hypertension in the Diabetic Patient:
Management of Hypertension in the Diabetic Patient: Nicolas W. Shammas, MS, MD Research Director, Cardiovascular Medicine, PC Presentation Objectives To review: The relationship between HTN, insulin resistance
More informationHypertension and diabetic nephropathy
Hypertension and diabetic nephropathy Elisabeth R. Mathiesen Professor, Chief Physician, Dr sci Dep. Of Endocrinology Rigshospitalet, University of Copenhagen Denmark Hypertension Brain Eye Heart Kidney
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationCardiac Problems in Diabetic Cardiology
ISSN 2348 392X BMH Medical Journal 2014;1(2):22-26 Review Article Cardiac Problems in Diabetic Cardiology KV Sahasranam MD, DM Baby Memorial Hospital, Kozhikode, Kerala, India. PIN: 673004 Address for
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationIntroduction. Factors affecting blood pressure: 1-COP = HR X SV mainly affect SBP. 2-TPR = diameter of arterioles X viscosity of blood affect DBP
Introduction Hypertension is a persistent elevation of blood pressure above 140 / 90 mmhg for more than three sitting. (0ptimal level
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More informationCourse: Exercise and Aging for Special Populations
Copyright EFS Inc. All Rights Reserved. Course: Exercise and Aging for Special Populations Session 2: Cardiovascular and Metabolic Disease Considerations for Exercise Program Design Presentation Created
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationWhat s New? Hypertension Canada Guidelines for the Management of Hypertension
What s New? 2017 Hypertension Canada Guidelines for the Management of Hypertension What s New? About This Booklet This booklet highlights key advancements and important, enduring aspects of the Hypertension
More informationMeasure Owner Designation. AMA-PCPI is the measure owner. NCQA is the measure owner. QIP/CMS is the measure owner. AMA-NCQA is the measure owner
2011 EHR Measure Specifications The specifications listed in this document have been updated to reflect clinical practice guidelines and applicable health informatics standards that are the most current
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)
ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during
More informationWelcome and Introduction
Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationBeta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center
Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center Beta-blockers: What s known 30 Years 30 Careers Physician clarity regarding
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationManagement of Cardiovascular Disease in Diabetes
Management of Cardiovascular Disease in Diabetes Radha J. Sarma, MBBS, FACP. FACC. FAHA. FASE Professor of Internal Medicine Western University of Health Sciences. Director, Heart and Vascular Center Western
More informationAmerican Academy of Insurance Medicine
American Academy of Insurance Medicine October 2012 Dr. Alison Moy Liberty Mutual Dr. John Kirkpatrick Thrivent Financial for Lutherans 1 59 year old male, diagnosed with T2DM six months ago Nonsmoker
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationDiabetes Control and Complications in Public Hospitals in Malaysia
ORIGINAL ARTICLE Diabetes Control and Complications in Public Hospitals in Malaysia Mafauzy M. FRCP For the Diabcare-Malaysia Study Group, Health Campus, Universiti Sains Malaysia, 16150 Kubang Kerian,
More informationDiabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center
Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationNurse-sensitive factors in hypertension management
Nurse-sensitive factors in hypertension management Hypertension treatment State of the Art Copper Hall 14:45-15:04 02/04/2011 Philippe van de Borne, MD, PhD Department of cardiology ULB-Erasme Hospital
More informationKidney and heart: dangerous liaisons. Luis M. RUILOPE (Madrid, Spain)
Kidney and heart: dangerous liaisons Luis M. RUILOPE (Madrid, Spain) Type 2 diabetes and renal disease: impact on cardiovascular outcomes The "heavyweights" of modifiable CVD risk factors Hypertension
More informationCardiovascular Complications in Diabetes
What is all the fuss about? Cardiovascular Complications in Diabetes Dina Shrestha MD Consultant Endocrinologist Norvic International Hospital and Medical College Hospital for Advanced Medicine and Surgery
More informationHypertension and Diabetes. Edward Shahady MD Medical Director Diabetes Master Clinician Program Florida Academy of Family Physicians
Hypertension and Diabetes Edward Shahady MD Medical Director Diabetes Master Clinician Program Florida Academy of Family Physicians Objectives Describe the prevalence of hypertension and hypertension control
More informationCLINICIAN INTERVIEW A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY. Interview with Ralph Rabkin, MD
A REVIEW OF THE CURRENT TREATMENT MODALITIES FOR DIABETIC NEPHROPATHY Interview with Ralph Rabkin, MD Dr Rabkin is Professor of Medicine, Emeritus, Active, at Stanford University School of Medicine, Stanford,
More informationSupplementary Online Content
Supplementary Online Content Afkarian M, Zelnick L, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014. JAMA. doi:10.1001/jama.2016.10924 emethods efigure
More informationRAS Blockade Across the CV Continuum
A Summary of Recent International Meetings RAS Blockade Across the CV Continuum Copyright New Evidence Presented at the 2009 Congress of the European Society of Cardiology (August 29-September 2, Barcelona)
More informationCoral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.
Coral Trials: A personal experience that challenges its results in patients with uncontrolled blood pressure.. Dr. Javier Ruiz Aburto, FACS, FICS Assistant Professor Ponce School of Medicine Puerto Rico
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More informationDiabetes Complications Recognition and Treatment
Diabetes Complications Recognition and Treatment Edward Shahady MD, FAAFP, ABCL Clinical Professor Family Medicine Medical Director Diabetes Master Clinician Program Diabetes is the most difficult of all
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationIndex. Foot Ankle Clin N Am 11 (2006) Note: Page numbers of article titles are in boldface type.
Foot Ankle Clin N Am 11 (2006) 865 869 Index Note: Page numbers of article titles are in boldface type. A Alpha-lipoic acid, in diabetic neuropathy, 764 Amputation(s), lower-extremity, in diabetes, 791
More information